Evidence map›Paper›PMID 42855689›Full record

Observational studyBMC pulmonary medicine2026

Subclinical hyperthyroidism is associated with reduced spirometric parameters in asymptomatic adults: a cross-sectional observational study with etiology-stratified analysis.

Berçem Afşar Karatepe, Burcu Özgür Çil, Zuhal Karaca Karagöz, Gülşah Altun, Derya Hoşgün

Abstract readObservational Study
In one paragraph

Observational study in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Berçem Afşar KaratepeInternal Medicine, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey. drbercem@hotmail.com.
Burcu Özgür ÇilInternal Medicine, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey.
Zuhal Karaca KaragözEndocrinology, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey.
Gülşah AltunInternal Medicine, Sivas Numune Hospital, Sivas, Turkey.
Derya HoşgünIntensive Care Unit, Ankara Atatürk Sanatorium Training and Research Hospital, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pulmonary effects of subclinical hyperthyroidism (SH) remain incompletely understood, and previous studies have been limited by reliance on absolute spirometric values, absence of etiology stratification, and inadequate control for anthropometric confounders. This cross-sectional study evaluated whether biochemically confirmed SH is independently associated with reduced spirometric parameters in asymptomatic adults, and whether these associations differ by SH etiology.

methodsA total of 148 outpatients aged 18-65 years were enrolled: 101 with confirmed SH (TSH < 0.4 mIU/L on two independent measurements ≥3 months apart, with normal fT4 and fT3) and 47 euthyroid controls (TSH 0.4-4.0 mIU/L). Individuals with pulmonary disease, cardiovascular disease, neuromuscular disorders, smoking history, or recent respiratory infection were excluded. Spirometry was performed according to ATS/ERS 2019 standards and results expressed as percent predicted (%pred) using European Community for Steel and Coal (ECSC) 1993 reference equations. To address demographic imbalances, a 1:1 age- and sex-matched sensitivity analysis (n = 34 per group) was performed. Multivariate linear regression controlled for age, sex, BMI, and height. SH etiology (Graves' disease, toxic multinodular goiter [TMNG], autonomous nodule, exogenous) and TSH suppression grade (Grade 1: 0.1-0.4 mIU/L; Grade 2: <0.1 mIU/L) were recorded

resultsIn the full study population, SH was associated with significantly lower FVC%pred (90.2 ± 22.9 vs. 104.9 ± 16.0, p < 0.001), FEV₁%pred (p < 0.001), PEF%pred (p = 0.004), and FEF₂₅-₇₅%pred (p = 0.006). The FEV₁/FVC ratio did not differ between groups (p = 0.670). A restrictive spirometric pattern was more prevalent in SH patients than controls (19% vs. 4%, p = 0.035). In the matched sample, FVC%pred (97.8 ± 15.6 vs. 106.8 ± 15.2, p = 0.018) and FEV₁%pred (95.4 ± 16.2 vs. 103.2 ± 15.8, p = 0.049) remained significantly lower. Multivariate regression confirmed SH as an independent correlate of lower FVC%pred (β = -7.09, 95% CI: -14.17 to -0.02, p = 0.049). Etiology-stratified analysis revealed that spirometric impairment was driven primarily by TMNG (FVC%pred 85.0 vs. 104.2 in controls, p < 0.001; FEV₁%pred 78.5 vs. 103.0 in controls, p < 0.001), whereas Graves' disease and autonomous nodule patients did not differ significantly from controls. Confirmatory TSH measurements demonstrated high temporal consistency (Spearman p = 0.960, p < 0.001), with 99/101 patients classified as persistent SH.

conclusionsIn this cross-sectional study, confirmed SH was independently associated with modest but statistically significant reductions in spirometric parameters, with the impairment concentrated in patients with TMNG etiology. As causal inference is not possible from a cross-sectional design, these findings should be regarded as hypothesis-generating. They support etiology-specific respiratory evaluation in selected SH patients and highlight the priority of longitudinal intervention studies to determine whether restoration of euthyroidism normalizes spirometric parameters.

Indexed as

HyperthyroidismAdolescentAdultAgedAsymptomatic DiseasesCross-Sectional StudiesFemaleForced Expiratory VolumeHumansMaleMiddle AgedSpirometryThyrotropinVital CapacityYoung AdultThyrotropinCross-sectional studyEtiologyPercent predictedPulmonary functionSpirometrySubclinical hyperthyroidismToxic multinodular goiter

Identifiers

PMID42855689
PMCPMC13651095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.